Ra Medical Systems Regains Compliance with NYSE American Continued Listing Standards
12/14/2022 - 04:33 PM
CARLSBAD, Calif. --(BUSINESS WIRE)--
Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces that it has received notification from the NYSE American LLC (“NYSE American”) that the Company has regained compliance with the NYSE American’s continued listing standard. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.
In the notification, the NYSE American informed the Company that as of December 9, 2022 , the below compliance (“.BS) indicator will no longer be disseminated and the Company has been removed from the NYSE American noncompliant issuers on the NYSE American’s website.
About Ra Medical Systems
Ra Medical Systems, Inc. is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System, is used as a tool in the treatment of peripheral artery disease.
View source version on businesswire.com : https://www.businesswire.com/news/home/20221214006025/en/
LHA Investor Relations
Jody Cain
jcain@lhai.com
Source: Ra Medical Systems, Inc.
RMED Rankings
N/A Ranked by Stock Gains
RMED Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Carlsbad
About RMED
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
